Chardan Capital analyst Gbola Amusa maintained a Hold rating on Voyager Therapeutics Inc (NASDAQ: VYGR) today and set a price target of $30. The company’s shares closed yesterday at $21.17.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 26.4% and a 55.7% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
Voyager Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $31.25.
See today’s analyst top recommended stocks >>
Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.93 million. In comparison, last year the company had a GAAP net loss of $16.65 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
